LAS VEGAS, Jan. 25, 2012 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today reports that umbilical cord blood stem cells have been successfully used to treat individuals with type 1 diabetes, highlighting the importance of storing stem cells at birth.
According to reports in Medical News Today http://www.medicalnewstoday.com/articles/240160.php and USA Today http://yourlife.usatoday.com/health/story/2012-01-14/Novel-stem-cell-treatment-may-hold-promise-for-type-1-diabetes/52536006/1, stem cells from cord blood have been used to "reeducate" the immune system T cells of people with type 1 diabetes so their pancreas started producing insulin again, reducing the amount of insulin they needed to inject. The treatment was even successful with long-standing diabetics who were believed to have no insulin-producing ability.
The scientists involved in the experiment said the treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.
Type 1 diabetes occurs when the body's immune system cells attack the insulin-producing cells in the pancreas. This means the cells don't produce enough insulin, and the lost insulin has to be replaced through injections for the patient to survive.
Also recently in the news, scientists at the University of Central Floridahttp://zeenews.india.com/news/health/health-news/umbilical-cord-stem-cells-that-yield-brain-cells_15311.html announced they have transformed stem cells from umbilical cords into other types of cells, which could be key in therapies for spinal cord injuries, multiple sclerosis and other nervous system diseases.
"Sometimes we forget, as we go about our daily activities, just how revolutionary is the storage and use of umbilical cord blood stem cells for medical treatment. We will continue to monitor the medical literature and keep our investors up-to-date on the amazing progress of these stem cells, which have already been used to treat or cure more than 70 diseases," said Matthew Schissler, co-founder and CEO. "Kalorama Information, a healthcare market research firm, estimates the markets for stem cell technologies soon could top $1 billionhttp://www.healthcarefinancenews.com/news/stem-cell-technologies-market-hit-700m-2012. It also states that umbilical cord blood is without controversy and that many people support the notion of routinely collecting cord blood at birth."
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
E & E Communications
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
SOURCE Cord Blood America, Inc.